Gilead Sciences Is Too Cheap To Ignore - Cramer's Lightning Round (6/22/18)

|
Includes: ALB, BHC, CARB, CRSP, FB, GILD, IRM, MCO, PRU, SNAP, TRST, TWTR
by: SA Editor Mohit Manghnani
Summary

Crispr Therapeutics is a speculative buy.

Buy Valeant Pharmaceuticals when it goes down $2.

Say no to Snap.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, June 22.

Bullish Calls

Gilead Sciences (NASDAQ:GILD): It's too low to sell and has a good challenge.

TrustCo Bank (NASDAQ:TRST): It's one of the good companies to own in this environment.

Crispr Therapeutics (NASDAQ:CRSP): This is a good gene-based company but it's a speculative buy.

Iron Mountain (NYSE:IRM): It's a consistent REIT stock with a nice yield.

Prudential Financial (NYSE:PRU): "I think people don't like the yield curve in Prudential. I happen to think Prudential's a very fine company and I have been recommending it for years when it's down. It's down. I'm recommending it."

Albemarle (NYSE:ALB): It's down 27% and it's a good time to buy.

Valeant Pharmaceuticals International (VRX): The stock is cooling down after a downgrade. Wait for it to go down $2 and buy it.

Moody's Corporation (NYSE:MCO): They have regained reputation after the financial crisis. It's a buy.

Bearish Calls

Snap (NYSE:SNAP): Cramer prefers Facebook (NASDAQ:FB) and Twitter (NYSE:TWTR).

Carbonite (NASDAQ:CARB): "To me, it's too much of a commodity to the data protection business. I'm not going to go there."

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up